| Literature DB >> 36077976 |
Yohannes E Messele1, Mauida Alkhallawi2, Tania Veltman2, Darren J Trott2, Joe P McMeniman3, Stephen P Kidd2, Wai Y Low1, Kiro R Petrovski1,2.
Abstract
This study investigated the antimicrobial resistance (AMR) profile of fecal Escherichia coli isolates from beef cattle (n = 150) at entry and exit from an Australian feedlot. Sample plating on MacConkey agar and Brilliance ESBL agar differentiated generic from extended-spectrum β-lactamase (ESBL)-producing E. coli, respectively. Resistance profiles were determined by minimum inhibitory concentration (MIC) testing and further analyzed by whole-genome sequencing (WGS). At entry, the prevalence of antimicrobial resistance to amoxicillin/clavulanic acid, ampicillin, streptomycin, and trimethoprim/sulfamethoxazole was very low (0.7%, each). At the exit, the resistance prevalence was moderate to tetracycline (17.8%) and low to ampicillin (5.4%), streptomycin (4.7%), and sulfisoxazole (3.9%). The most common AMR genes observed in phenotypically resistant isolates were tet(B) (43.2%), aph(3″)-Ib and aph(6)-Id (32.4%), blaTEM-1B, and sul2 (24.3%, each), which are responsible for resistance to tetracyclines, aminoglycosides, β-lactams, and sulfonamides, respectively. The ESBL-producing E. coli were recovered from one sample (0.7%) obtained at entry and six samples (4.0%) at the exit. The ESBL-producing E. coli harbored blaTEM (29.7%), blaCTX m(13.5%), and blaCMY (5.4%). The resistance phenotypes were highly correlated with resistance genotypes (r ≥ 0.85: p < 0.05). This study demonstrated that E. coli isolated from feedlot beef cattle can harbour AMR genes, but the low incidence of medically important resistance reflected the prudent antimicrobial use in the Australian industry.Entities:
Keywords: antimicrobial resistance genes; antimicrobial resistance surveillance; cattle feedlot; cattle slaughterhouse; multidrug resistance
Year: 2022 PMID: 36077976 PMCID: PMC9454709 DOI: 10.3390/ani12172256
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Tested dilution ranges and breakpoints used for antimicrobial susceptibility testing.
| Antimicrobial Agent | Tested Range | Breakpoints |
|---|---|---|
| Amoxicillin/Clavulanic acid | 1–32 | ≥32 |
| Ampicillin | 1–32 | ≥32 |
| Azithromycin | 0.12–16 | >16 |
| Cefoxitin | 0.5–32 | ≥32 |
| Ceftiofur | 0.12–8 | ≥8 |
| Ceftriaxone | 0.25–64 | ≥4 |
| Chloramphenicol | 2–32 | ≥32 |
| Ciprofloxacin | 0.015–4 | ≥1 |
| Gentamicin | 0.25–16 | ≥16 |
| Nalidixic acid | 0.5–32 | ≥32 |
| Streptomycin | 2–64 | ≥64 |
| Sulfisoxazole | 16–256 | > 256 |
| Tetracycline | 4–32 | ≥16 |
| Trimethoprim/Sulfamethoxazole | 0.12–4 | ≥4 |
Antimicrobial susceptibility testing results for generic Escherichia coli recovered on MacConkey agar from cattle rectal feces obtained at entry into the feedlot (n = 135).
| Antimicrobial Class | Antimicrobial Agent | Prevalence (95% CI) | Isolate Prevalence (%)* for Each MIC Value Tested (µg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | |||
| Aminoglycosides | Gentamicin | 0.0 (0.00–2.77) | 63.7 | 35.6 | 0.7 | |||||||||||||
| Streptomycin | 0.7 (0.13–4.08) | 55.6 | 43.0 | 0.7 | 0.7 | |||||||||||||
| β-lactams | Ampicillin | 0.7 (0.13–4.08) | 6.7 | 46.7 | 43.7 | 0.7 | 1.5 | 0.7 | ||||||||||
| Amoxicillin/Clavulanic acid | 0.7 (0.13–4.08) | 3.7 | 15.6 | 65.9 | 13.3 | 0.7 | 0.7 | |||||||||||
| Cefoxitin | 0.0 (0.00–2.77) | 26.7 | 64.4 | 8.9 | ||||||||||||||
| Ceftiofur | 0.0 (0.00–2.77) | 0.7 | 14.1 | 79.2 | 5.2 | 0.7 | ||||||||||||
| Ceftriaxone | 0.0 (0.00–2.77) | 97 | 1.5 | 1.5 | ||||||||||||||
| Folate pathway | Sulfisoxazole | 0.0 (0.00–2.77) | 88.1 | 11.0 | 0.7 | |||||||||||||
| Trimethoprim/ | 0.7 (0.13–4.08) | 98.5 | 0.7 | 0.7 | ||||||||||||||
| Macrolides | Azithromycin | 0.0 (0.00–2.77) | 3.0 | 15.6 | 36.3 | 44.4 | 0.7 | |||||||||||
| Phenicols | Chloramphenicol | 0.0 (0.00–2.77) | 3.0 | 48.9 | 47.4 | 0.7 | ||||||||||||
| Fluoroquinolones | Ciprofloxacin | 0.0 (0.00–2.77) | 97.8 | 1.5 | 0.7 | |||||||||||||
| Nalidixic acid | 0.0 (0.00–2.77) | 0.7 | 13.3 | 81.5 | 4.4 | |||||||||||||
| Tetracycline | Tetracycline | 0.0 (0.00–2.77) | 99.3 | |||||||||||||||
* The white area shows the dilution range, and the shaded areas are MICs beyond the concentration tested for each antimicrobial. Solid vertical lines show the breakpoints used for classifying an isolate as resistant.
Antimicrobial susceptibility testing results for generic Escherichia coli (n = 129; GE) and ESBL-producing E. coli (n = 6; EE) isolated from rectal fecal samples collected at the abattoir post-slaughter.
| Antimicrobial Class | Antimicrobial Agent | Prevalence (95% CI) | Isolate Prevalence (%) * for Each MIC Value Tested (µg/mL) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | ||||
| Aminoglycosides | Gentamicin | GE | 0.0 (0.00–2.89) | 3.9 | 72.8 | 23.2 | |||||||||||||
| EE | 0.0 (0.00–39.03) | 66.7 | 16.7 | 16.7 | |||||||||||||||
| Streptomycin | GE | 4.7 (1.16–16.8) | 53.5 | 39.5 | 1.5 | 0.8 | 3.9 | 0.8 | |||||||||||
| EE | 66.7 (53.51–75.88) | 33.3 | 33.3 | 33.3 | |||||||||||||||
| β–lactams | Ampicillin | GE | 5.4 (1.34–20.02) | 15.5 | 47.3 | 28.7 | 2.3 | 0.8 | 5.4 | ||||||||||
| EE | 100.0 (96.00–100.00) | 100 | |||||||||||||||||
| Amoxicillin/Clavulanic acid | GE | 0.8 (0.11–5.75) | 6.2 | 35.6 | 47.3 | 10.1 | 0.8 | ||||||||||||
| EE | 16.7 (8.16–31.05) | 33.3 | 50.0 | 16.7 | |||||||||||||||
| Cefoxitin | GE | 0.8 (0.11–5.75) | 11.6 | 31.8 | 36.4 | 19.4 | 0.8 | ||||||||||||
| EE | 16.7 (8.16–31.05) | 66.7 | 16.7 | 16.7 | |||||||||||||||
| Ceftiofur | GE | 0.0 (0.00–2.89) | 12.4 | 28.7 | 52.7 | 6.2 | |||||||||||||
| EE | 100.0 (96.0–100.0) | 100.0 | |||||||||||||||||
| Ceftriaxone | GE | 0.0 (0.00–2.89) | 100.0 | ||||||||||||||||
| EE | 100.0 (96.0–100.0) | 16.7 | 83.3 | ||||||||||||||||
| Folate pathway | Sulfisoxazole | GE | 3.9 (1.82–8.45) | 92.2 | 3.9 | 3.9 | |||||||||||||
| EE | 66.7 (53.51–75.88) | 33.3 | 66.7 | ||||||||||||||||
| Trimethoprim/ | GE | 0.0 (0.00–2.89) | 100 | ||||||||||||||||
| EE | 33.3 (23.68–45.70) | 33.3 | 33.3 | 33.3 | |||||||||||||||
| Macrolides | Azithromycin | GE | 0.0 (0.00–2.89) | 10.1 | 38.7 | 51.2 | |||||||||||||
| EE | 50.0 (34.83–65.64) | 33.3 | 16.7 | 50.0 | |||||||||||||||
| Phenicols | Chloramphenicol | GE | 0.0 (0.00–2.89) | 0.8 | 32.6 | 65.1 | 1.5 | ||||||||||||
| EE | 16.7 (8.16–31.05) | 66.7 | 16.7 | 16.7 | |||||||||||||||
| Fluoroquinolones | Ciprofloxacin | GE | 0.0 (0.00–2.89) | 96.9 | 3.1 | ||||||||||||||
| EE | 0.0 (0.00–39.03 | 66.7 | 16.7 | 16.7 | |||||||||||||||
| Nalidixic acid | GE | 0.0 (0.00–2.89) | 11.6 | 77.5 | 10.8 | ||||||||||||||
| EE | 0.0 (0.00–39.03) | 50.0 | 33.3 | 16.7 | |||||||||||||||
| Tetracycline | Tetracycline | GE | 17.8 (12.66–24.43) | 81.4 | 0.8 | 2.3 | 15.5 | ||||||||||||
| EE | 83.3 (67.50–93.75) | 16.7 | 83.3 | ||||||||||||||||
* The white area shows the dilution range, and the shaded areas are MICs beyond the concentration tested for each antimicrobial. Solid vertical lines show the breakpoints used for classifying an isolate as resistant.
Figure 1Antimicrobial resistance profiles of Escherichia coli recovered from MacConkey agar (GE) and ESBL agar (EE) at entry into the feedlot (Induction) and at the abattoir post-slaughter (Exit). GE, generic E. coli; EE, ESBL-producing E. coli. Only two (1.5%; low) feedlot entry GE isolates were resistant to at least one antimicrobial. The single (0.7%; very low) EE isolate obtained at feedlot entry exhibited resistance to β-lactams (amoxicillin/clavulanic acid, ampicillin, cefoxitin, ceftiofur, and ceftriaxone) and tetracycline. By comparison, the six EE isolates obtained post-slaughter were resistant to one (16.7%), three (16.7%), four (16.7%), and five (50%) antimicrobial classes.
The identification of antimicrobial resistance genes in Escherichia coli isolates (n = 37) recovered from fecal samples obtained at entry to the feedlot and post-slaughter at the abattoir.
| Antimicrobial Class | Resistance Phenotype | Resistance Gene | Number of Isolates (%) |
|---|---|---|---|
| Aminoglycosides | STR |
| 12 (32.4) |
| Aminoglycosides | STR |
| 12 (32.4) |
| Aminoglycosides | STR, KAN |
| 1 (2.7) |
| Aminoglycosides | KAN |
| 1 (2.7) |
| Aminoglycosides | HYG |
| 1 (2.7) |
| Aminoglycosides | GEN |
| 1 (2.7) |
| β-lactams | AUG, AXO, FOX, XNL |
| 2 (5.4) |
| β-lactams | AMP, AXO, XNL |
| 3 (8.1) |
| β-lactams | AMP, AXO, XNL |
| 2 (5.4) |
| β-lactams | AMP, AXO, XNL |
| 9 (24.3) |
| β-lactams | AMP |
| 2 (5.4) |
| Macrolides | AZI, ERY |
| 3 (8.1) |
| Macrolides | AZI, ERY |
| 1 (2.7) |
| Macrolides | AZI, ERY |
| 1 (2.7) |
| Folate synthesis inhibitors | FIS |
| 1 (2.7) |
| Folate synthesis inhibitors | FIS |
| 9 (24.3) |
| Folate synthesis inhibitors | FIS |
| 1 (2.7) |
| Folate synthesis inhibitors | SXT |
| 2 (5.4) |
| Folate synthesis inhibitors | SXT |
| 1 (2.7) |
| Folate synthesis inhibitors | SXT |
| 1 (2.7) |
| Phenicols | CHL |
| 1 (2.7) |
| Fluoroquinolones | CIP |
| 1 (2.7) |
| Tetracyclines | TET |
| 12 (32.4) |
| Tetracyclines | TET |
| 16 (43.2) |
AUG, amoxicillin/clavulanic acid; AMP, ampicillin; AZI, azithromycin; AXO, ceftriaxone; CHL, chloramphenicol; ERY, erythromycin; FIS, sulfisoxazole; FOX, cefoxitin; GEN; gentamicin; HYG, hygromycin; STR, streptomycin; TET, tetracycline; SXT, trimethoprim/sulfamethoxazole; XNL, ceftiofur.
The antimicrobial resistance pattern of E. coli recovered from fecal samples obtained at entry to the feedlot and post-slaughter.
| Antimicrobial Classes Pattern | Total no. of Isolates (%) | Resistance Pattern (no. of Isolates) | ||
|---|---|---|---|---|
| Phenotypic (37) | Genotypic (37) | Phenotypic (MIC) | Genotypic (Resistance Gene) | |
| All susceptible | 4 (10.8) | 5 (13.5) | 4 | 5 |
| 1 | 16 (43.2) | 15 (40.5) | AMP (1) | |
| AMP-AUG-FOX-XNL-AXO (1) | ||||
| FIS (1) | ||||
| TET (13) | ||||
| 2 | 5 (13.5) | 3 (8.1) | AMP-AUG-AXO-FOX-TET-XNL (1) | |
| AMP-TET (3) | ||||
| FIS-TET (1) | ||||
| 3 | 8 (21.6) | 10 (27.0) | AMP-STR-SXT (1) | |
| AMP-STR-TET (3) | ||||
| AMP-AXO-AZI-TET-XNL (1) | ||||
| FIS-STR-TET (3) | ||||
| 4 | 1 (2.7) | 1 (2.7) | AMP-AXO-FIS-STR-SXT-TET-XNL (1) | aph(3″)-Ib, aph(6)-Id, blaCTX-M-15, blaTEM-1B,dfrA14, sul2, tet(A) (1) |
| 5 | 3 (8.1) | 2(5.4) | AMP-AXO-AZI-FIS-STR-TET-XNL (2) | aph(3″)-Ib, aph(6)-Id, blaCTX-M-27,mph(A), sul2, tet(A) (2) |
| AMP-AXO-CHL-FIS-STR-SXT-TET-XNL (1) | ||||
| 6 | 1 (2.7) | aac(3)-IV, ant(3″)-Ia, aph(3″)-Ib, aph(4)-Ia, aph(6)-Id, blaCTX-M-15, blaTEM-1B, cmlA1, dfrA12, qnrS1, sul1, sul3,tet(A) (1) | ||
| Non-MDR | 21 (56.7) | 18 (48.6) | ||
| MDR | 12 (32.4) | 14 (37.8) | ||
| Resistance | 33 (89.2) | 32(86.5) | ||
AUG, amoxicillin/clavulanic acid; AMP, ampicillin; AZI, azithromycin; AXO, ceftriaxone; CHL, chloramphenicol; FIS, sulfisoxazole; FOX, cefoxitin; STR, streptomycin; TET, tetracycline; SXT, trimethoprim/sulfamethoxazole; XNL, ceftiofur.
Figure 2The Pearson correlation coefficient matrix between phenotypic (P) and genotypic (G) AMR in Escherichia coli isolated from beef feedlot and abattoir. AUG, amoxicillin/clavulanic acid; AMP, ampicillin; AZI, azithromycin; AXO, ceftriaxone; CHL, chloramphenicol; FIS, sulfisoxazole; FOX, cefoxitin; STR, streptomycin; TET, tetracycline; SXT, trimethoprim/sulfamethoxazole; XNL, ceftiofur. According to the scale bar shown at the bottom, the colours indicate different correlation coefficient values. The circle size is proportional to the correlation coefficients. Asterisks indicate the significance of the Pearson correlation coefficient (p < 0.05).